VNDA Vanda Pharmaceuticals Inc.

14
+0.18  (+1%)
Previous Close 13.82
Open 13.87
Price To Book 2.66
Market Cap 741,491,464
Shares 52,963,676
Volume 1,045,663
Short Ratio
Av. Daily Volume 764,587

NewsSee all news

  1. Is Vanda Pharmaceuticals Inc. (VNDA) A Good Stock To Buy?
  2. Vanda Pharmaceuticals Announces Participation at the Jefferies 2019 Global Healthcare Conference
  3. Tradipitant in the Treatment of Gastroparesis: Vanda Presents Clinical Trial Results at DDW 2019
  4. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA): Will The Growth Last?
  5. Should Investors Worry Over a Sluggish First Quarter for Vanda Pharmaceuticals?

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated 2Q 2019.
Tradipitant
Gastroparesis
PK trial initiated with full enrollment completed 4Q 2017.
HETLIOZ (tasimelteon) - pediatric formulation
Insomnia
Approved May 26, 2016.
Fanapt
Supplemental New Drug Application (sNDA) as a maintenance treatment of schizophrenia in adults.
Approved January 31, 2014.
HETLIOZ (tasimelteon)
Insomnia
PDUFA date August 16, 2019.
HETLIOZ (tasimelteon)
Jet Lag Disorder
Phase 3 data released December 10, 2018 - one of two primary endpoints met. sNDA filing due 3Q 2019.
HETLIOZ (tasimelteon)
Smith-Magenis Syndrome
Phase 3 data due 1H 2020.
Tradipitant
Atopic dermatitis
Phase 1 initiated October 2018.
VTR-297
Hematologic malignancies
Phase 2 data due 3Q 2019.
Tradipitant
Motion sickness

Latest News

  1. Is Vanda Pharmaceuticals Inc. (VNDA) A Good Stock To Buy?
  2. Vanda Pharmaceuticals Announces Participation at the Jefferies 2019 Global Healthcare Conference
  3. Tradipitant in the Treatment of Gastroparesis: Vanda Presents Clinical Trial Results at DDW 2019
  4. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA): Will The Growth Last?
  5. Should Investors Worry Over a Sluggish First Quarter for Vanda Pharmaceuticals?
  6. Edited Transcript of VNDA earnings conference call or presentation 1-May-19 8:30pm GMT
  7. Vanda Pharmaceuticals (VNDA) Q1 2019 Earnings Call Transcript
  8. Vanda Pharmaceuticals (VNDA) Q1 Earnings Top Estimates
  9. Vanda: 1Q Earnings Snapshot
  10. Vanda Pharmaceuticals Reports First Quarter 2019 Financial Results
  11. Vanda Pharmaceuticals, Inc. to Host Earnings Call
  12. DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Vanda Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
  13. FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of VNDA, CNDT and MBT
  14. FINAL DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Vanda Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
  15. CLASS ACTION UPDATE for VNDA, CRCM, ARA and INVVY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
  16. FRIDAY DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Vanda Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
  17. CLASS ACTION UPDATE for VNDA, CTL and INGN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
  18. SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Vanda Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
  19. CLASS ACTION UPDATE for AVEO, KHC and VNDA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders